Author

Catello Vollono

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Beyond seizure control: Non-seizure-related outcomes in focal-onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study.

OBJECTIVE Cenobamate is approved for treatment of focal seizures in adults, but evidence on non-seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal-onsEt SeizureS (BLESS) study evaluated patient- and clinician-reported outcomes for up to 52 weeks of cenobamate trea...

Simona Lattanzi, G. d'Orsi, M. T. Di Claudio et al. · Epilepsia · 0 citations

Open access Oct 2026

Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort).

INTRODUCTION A substantial proportion of patients with chronic migraine (CM) experience persistent disability despite advanced preventive monotherapies, including onabotulinumtoxinA (BoNT-A) and calcitonin gene-related peptide (CGRP)-targeted drugs. Evidence supporting combination strategies remains limited. We evaluat...

M. Romozzi, L. Iannone, A. Russo et al. · Neurological Therapeutics · 0 citations

Review Open access Oct 2026

Preliminary evidence of long‐term safety and effectiveness of anti‐CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52‐week follow‐up retrospective study

Abstract Migraine and epilepsy frequently coexist, but evidence on the safety of calcitonin gene‐related peptide (CGRP)‐targeting therapies in people with epilepsy is lacking. We evaluated long‐term migraine and epilepsy outcomes in a real‐world multicenter retrospective cohort of adults with comorbid migraine and epil...

Marina Romozzi, Andrea Burgalassi, Francesco Ceriello et al. · Epilepsia Open · 0 citations